Yourgene Health PLC Private Investor Presentation
October 01 2019 - 1:01AM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
01 October 2019
Yourgene Health plc
("Yourgene" or the "Company")
Private Investor Presentation
Manchester, UK - 1 October 2019: Yourgene (AIM: YGEN), a leading
international molecular diagnostics group, announces that it will
be holding a private investor presentation on Thursday 24 October
2019, providing an opportunity for investors to hear directly from
management regarding Company strategy and future growth
opportunities.
The presentation will take place at the Brand Exchange, 3
Birchin Lane, London, EC3V 9BW. Doors will open at 4.30pm for a
4.45pm start. If you would like to register for the investor
presentation, or require further information, please contact
Walbrook PR on 020 7933 8780 or email yourgene@walbrookpr.com.
No new material information will be disclosed at the event and
the presentation will be made available on the Company's website
here:
www.yourgene-health.com/investors/company-information/investor-presentations
For further information please contact:
Yourgene Health plc Tel: +44 (0)161 667 1053
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Stifel Nicolaus Europe Limited (Sole Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations) Mob: 07980 541 893 / 07584 391 303
Paul McManus / Lianne Cawthorne
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate
molecular diagnostic solutions, primarily for reproductive health.
The Group's products include non-invasive prenatal tests (NIPT) for
Down's Syndrome and other genetic disorders, Cystic Fibrosis
screening tests, invasive rapid aneuploidy tests, male infertility
tests and genetic disease tests. Yourgene's commercial footprint is
already established in the UK, Europe, the Middle East, Africa and
Asia.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions. Through our technical
expertise and partnerships, Yourgene Health is also extending its
genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei and Singapore, and is listed on the London Stock
Exchange's AIM market under the ticker "YGEN". For more
information, visit www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAWGUPABUPBGQU
(END) Dow Jones Newswires
October 01, 2019 02:01 ET (06:01 GMT)
Premaitha (LSE:NIPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Premaitha (LSE:NIPT)
Historical Stock Chart
From Jul 2023 to Jul 2024